{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010805",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010805_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"antacids\" outputclass=\"int-drug\">antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rilpivirine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3830\">rilpivirine</xref></ph> should be taken 4 hours before or 2 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   antacids   are predicted to   decrease   the exposure to   oral   rilpivirine .  Manufacturer advises  rilpivirine  should be taken 4 hours before or 2 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Antacids</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010806",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010806_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">Apalutamide</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apalutamide   markedly   decreases   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010807",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010807_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bosentan\" outputclass=\"int-drug\">Bosentan</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bosentan   is predicted to   decrease   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosentan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010808",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010808_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-drug\">calcium carbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rilpivirine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3830\">rilpivirine</xref></ph> should be taken 4 hours before or 2 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   -containing antacids   are predicted to   decrease   the exposure to   oral   rilpivirine .  Manufacturer advises  rilpivirine  should be taken 4 hours before or 2 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium carbonate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010809",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010809_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   markedly   decreases   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010810",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010810_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cimetidine\" outputclass=\"int-drug\">Cimetidine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"cimetidine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/cimetidine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP404\">cimetidine</xref></ph> should be taken 12 hours before or 4 hours after <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rilpivirine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3830\">rilpivirine</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Cimetidine   is predicted to   decrease   the exposure to   rilpivirine .  Manufacturer advises  cimetidine  should be taken 12 hours before or 4 hours after  rilpivirine .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cimetidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010811",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010811_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabrafenib\" outputclass=\"int-drug\">Dabrafenib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabrafenib   is predicted to   decrease   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabrafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010812",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010812_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">Dexamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid multiple-dose dexamethasone</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexamethasone   is predicted to   decrease   the concentration of   rilpivirine .  Manufacturer advises avoid multiple-dose dexamethasone .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010813",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010813_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">Efavirenz</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Efavirenz   is predicted to   decrease   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010814",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010814_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   markedly   decreases   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010815",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010815_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"esomeprazole\" outputclass=\"int-drug\">Esomeprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Esomeprazole   is predicted to   decrease   the exposure to   oral   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esomeprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010816",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010816_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etravirine\" outputclass=\"int-drug\">Etravirine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etravirine   is predicted to   decrease   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etravirine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010817",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010817_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"famotidine\" outputclass=\"int-drug\">Famotidine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"famotidine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/famotidine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP407\">famotidine</xref></ph> should be taken 12 hours before or 4 hours after <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rilpivirine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3830\">rilpivirine</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Famotidine   is predicted to   decrease   the exposure to   rilpivirine .  Manufacturer advises  famotidine  should be taken 12 hours before or 4 hours after  rilpivirine .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Famotidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010818",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010818_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   markedly   decreases   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010819",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010819_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lansoprazole\" outputclass=\"int-drug\">Lansoprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lansoprazole   is predicted to   decrease   the exposure to   oral   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lansoprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010820",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010820_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mitotane   markedly   decreases   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010821",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010821_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nevirapine\" outputclass=\"int-drug\">Nevirapine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nevirapine   is predicted to   decrease   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nevirapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010822",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010822_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nizatidine\" outputclass=\"int-drug\">Nizatidine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"nizatidine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/nizatidine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP410\">nizatidine</xref></ph> should be taken 12 hours before or 4 hours after <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rilpivirine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3830\">rilpivirine</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nizatidine   is predicted to   decrease   the exposure to   rilpivirine .  Manufacturer advises  nizatidine  should be taken 12 hours before or 4 hours after  rilpivirine .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nizatidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010823",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010823_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"omeprazole\" outputclass=\"int-drug\">Omeprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Omeprazole   is predicted to   decrease   the exposure to   oral   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omeprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010824",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010824_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxcarbazepine\" outputclass=\"int-drug\">Oxcarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxcarbazepine   is predicted to   decrease   the concentration of   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxcarbazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010825",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010825_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"pantoprazole\" outputclass=\"int-drug\">Pantoprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Pantoprazole   is predicted to   decrease   the exposure to   oral   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pantoprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010826",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010826_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   markedly   decreases   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010827",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010827_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   markedly   decreases   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010828",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010828_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Primidone   markedly   decreases   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010829",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010829_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rabeprazole\" outputclass=\"int-drug\">Rabeprazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rabeprazole   is predicted to   decrease   the exposure to   oral   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rabeprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010830",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010830_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ranitidine\" outputclass=\"int-drug\">Ranitidine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"ranitidine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/ranitidine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP413\">ranitidine</xref></ph> should be taken 12 hours before or 4 hours after <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rilpivirine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3830\">rilpivirine</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ranitidine   is predicted to   decrease   the exposure to   rilpivirine .  Manufacturer advises  ranitidine  should be taken 12 hours before or 4 hours after  rilpivirine .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ranitidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010831",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010831_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifabutin\" outputclass=\"int-drug\">Rifabutin</ph> <ph outputclass=\"int-magnitude\">modestly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose—consult product literature</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifabutin   modestly   decreases   the exposure to   rilpivirine .  Manufacturer advises avoid or adjust dose—consult product literature .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifabutin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010832",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010832_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   markedly   decreases   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010833",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010833_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"sodium bicarbonate\" outputclass=\"int-drug\">sodium bicarbonate</ph> <ph outputclass=\"int-substanceQualifier\">-containing antacids</ph> <ph outputclass=\"int-effectQualifier\">are predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/rilpivirine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP3830\">rilpivirine</xref></ph> should be taken 4 hours before or 2 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oral   sodium bicarbonate   -containing antacids   are predicted to   decrease   the exposure to   oral   rilpivirine .  Manufacturer advises  rilpivirine  should be taken 4 hours before or 2 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium bicarbonate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010834",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010834_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sodium zirconium cyclosilicate\" outputclass=\"int-drug\">Sodium zirconium cyclosilicate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sodium zirconium cyclosilicate   is predicted to   decrease   the exposure to   rilpivirine .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium zirconium cyclosilicate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010835",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2#bnf_i1643858010835_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rilpivirine\" outputclass=\"int-heading-drug\">rilpivirine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "St John's wort   is predicted to   decrease   the exposure to   rilpivirine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				}
			],
			"hasSearchLabel": " Rilpivirine  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/rilpivirine-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Rilpivirine </title>"
			},
			"rdfs:label": "rilpivirine"
		}
	]
}